{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Muscle-Invasive+Bladder+Cancer&page=11", "query": { "condition": "Muscle-Invasive Bladder Cancer", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 291, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Muscle-Invasive+Bladder+Cancer&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Muscle-Invasive+Bladder+Cancer&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T09:08:06.029Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07725796", "title": "A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder (Urothelial, Transitional Cell) Cancer", "NMIBC", "Urothelial Carcinoma Bladder", "Urothelial Carcinoma in Situ", "Urothelial Carcinoma Recurrent", "Urothelial Carcinoma of the Urinary Bladder", "Non-Muscle Invasive Bladder Carcinoma", "Non-muscle Invasive Bladder Cancer (NMIBC)" ], "interventions": [ { "name": "UGN-501", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-09-28", "completion_date": "2029-08-02", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 15, "location_summary": "Queen Creek, Arizona • Bakersfield, California • Murrieta, California + 12 more", "locations": [ { "city": "Queen Creek", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Murrieta", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07725796" }, { "nct_id": "NCT06190197", "title": "Prophylactic Antibiotics in Cystectomy With Diversion", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Muscle-Invasive Bladder Carcinoma", "Radical Cystectomy", "Ileal Conduit", "Neobladder Diversion" ], "interventions": [ { "name": "Prophylactic antibiotics postoperatively.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-05-13", "completion_date": "2027-10-15", "has_results": false, "last_update_posted_date": "2025-11-17", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06190197" }, { "nct_id": "NCT03775265", "title": "Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Urothelial Carcinoma", "Muscle Invasive Bladder Carcinoma", "Stage II Bladder Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy of Bladder", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cystoscopy", "type": "PROCEDURE" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Transurethral Resection of Bladder Tumor", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 475, "start_date": "2019-06-03", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 365, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 273 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775265" }, { "nct_id": "NCT05014139", "title": "A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Neoplasms", "Carcinoma in Situ", "Carcinoma Transitional Cell", "Non-muscle Invasive Bladder Cancer", "NMIBC" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-12-07", "completion_date": "2025-09-22", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 21, "location_summary": "Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05014139" }, { "nct_id": "NCT00003701", "title": "Combination Chemotherapy in Treating Patients With Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer", "Urethral Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "0 Years to 120 Years" }, "enrollment_count": 490, "start_date": "1999-04-02", "completion_date": "2007-06-15", "has_results": false, "last_update_posted_date": "2023-06-15", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 13, "location_summary": "Decatur, Georgia • Indianapolis, Indiana • Flemington, New Jersey + 9 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Flemington", "state": "New Jersey" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Millville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003701" }, { "nct_id": "NCT05316155", "title": "Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Muscle Invasive Bladder Neoplasms" ], "interventions": [ { "name": "Erdafitinib Intravesical Delivery System", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-04-11", "completion_date": "2029-07-24", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Largo", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05316155" }, { "nct_id": "NCT04241185", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Bladder Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Conventional Radiotherapy (Bladder only)", "type": "RADIATION" }, { "name": "Conventional Radiotherapy (Bladder and pelvic nodes)", "type": "RADIATION" }, { "name": "Hypofractionated Radiotherapy (Bladder only)", "type": "RADIATION" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Mitomycin C (MMC)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo to Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2020-05-19", "completion_date": "2031-11-01", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 24, "location_summary": "Washington D.C., District of Columbia • Bay Pines, Florida • Orlando, Florida + 20 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bay Pines", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Pikeville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04241185" }, { "nct_id": "NCT07720284", "title": "An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "High-risk Muscle Invasive Urothelial Carcinoma" ], "interventions": [ { "name": "Dato-DXd", "type": "DRUG" }, { "name": "Rilvegostomig", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 915, "start_date": "2026-07-16", "completion_date": "2032-11-23", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 19, "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more", "locations": [ { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07720284" }, { "nct_id": "NCT00583349", "title": "Intravesicular Abraxane for Treatment-Refractory Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Abraxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2008-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2025-02-17", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00583349" }, { "nct_id": "NCT03609216", "title": "Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infiltrating Bladder Urothelial Carcinoma", "Stage II Bladder Urothelial Carcinoma", "Stage III Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Radical Cystectomy", "type": "PROCEDURE" }, { "name": "Chemoradiotherapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 237, "start_date": "2018-12-10", "completion_date": "2030-10-14", "has_results": false, "last_update_posted_date": "2026-10-16", "last_synced_at": "2026-10-20T09:08:06.029Z", "location_count": 424, "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03609216" } ] }